193 related articles for article (PubMed ID: 29786782)
1. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
Reguera-Nuñez E; Man S; Xu P; Kerbel RS
Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
[TBL] [Abstract][Full Text] [Related]
2. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib.
Jedeszko C; Paez-Ribes M; Di Desidero T; Man S; Lee CR; Xu P; Bjarnason GA; Bocci G; Kerbel RS
Sci Transl Med; 2015 Apr; 7(282):282ra50. PubMed ID: 25855496
[TBL] [Abstract][Full Text] [Related]
3. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma.
Keisner SV; Shah SR
Drugs; 2011 Mar; 71(4):443-54. PubMed ID: 21395357
[TBL] [Abstract][Full Text] [Related]
4. Pazopanib for the treatment of metastatic renal cell carcinoma.
Pick AM; Nystrom KK
Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.
Bridgeman VL; Wan E; Foo S; Nathan MR; Welti JC; Frentzas S; Vermeulen PB; Preece N; Springer CJ; Powles T; Nathan PD; Larkin J; Gore M; Vasudev NS; Reynolds AR
Mol Cancer Ther; 2016 Jan; 15(1):172-83. PubMed ID: 26487278
[TBL] [Abstract][Full Text] [Related]
6. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
[TBL] [Abstract][Full Text] [Related]
7. Pazopanib: an orally administered multi-targeted tyrosine kinase inhibitor for locally advanced or metastatic renal cell carcinoma.
Koc G; Wang X; Luo Y
Can J Urol; 2011 Dec; 18(6):5991-7. PubMed ID: 22166325
[TBL] [Abstract][Full Text] [Related]
8. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
9. Evidence and Clinical Relevance of Tumor Flare in Patients Who Discontinue Tyrosine Kinase Inhibitors for Treatment of Metastatic Renal Cell Carcinoma.
Iacovelli R; Massari F; Albiges L; Loriot Y; Massard C; Fizazi K; Escudier B
Eur Urol; 2015 Jul; 68(1):154-60. PubMed ID: 25466943
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a single institution experience.
Matrana MR; Bathala T; Campbell MT; Duran C; Shetty A; Teegavarapu P; Kalra S; Xiao L; Atkinson B; Corn P; Jonasch E; Tannir NM
BJU Int; 2016 Aug; 118(2):264-71. PubMed ID: 26573089
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
Zivi A; Cerbone L; Recine F; Sternberg CN
Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography.
Zhu XD; Zhang JB; Fan PL; Xiong YQ; Zhuang PY; Zhang W; Xu HX; Gao DM; Kong LQ; Wang L; Wu WZ; Tang ZY; Ding H; Sun HC
BMC Cancer; 2011 Jan; 11():28. PubMed ID: 21251271
[TBL] [Abstract][Full Text] [Related]
15. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study.
Hammers HJ; Verheul HM; Salumbides B; Sharma R; Rudek M; Jaspers J; Shah P; Ellis L; Shen L; Paesante S; Dykema K; Furge K; Teh BT; Netto G; Pili R
Mol Cancer Ther; 2010 Jun; 9(6):1525-35. PubMed ID: 20501804
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.
Négrier S; Pérol D; Bahleda R; Hollebecque A; Chatelut E; Boyle H; Cassier P; Metzger S; Blanc E; Soria JC; Escudier B
BMC Cancer; 2017 Aug; 17(1):547. PubMed ID: 28810837
[TBL] [Abstract][Full Text] [Related]
18. Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK; Aston J; Pollack M; Du L; Koyama T; Chism DD
Oncologist; 2018 Jun; 23(6):686-692. PubMed ID: 29487220
[TBL] [Abstract][Full Text] [Related]
19. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells.
Shablak A; Gilham DE; Hawkins RE; Elkord E
Expert Opin Pharmacother; 2014 Aug; 15(11):1489-99. PubMed ID: 24890457
[TBL] [Abstract][Full Text] [Related]
20. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma.
Bukowski RM
Expert Rev Anticancer Ther; 2010 May; 10(5):635-45. PubMed ID: 20469994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
